Given the broad range of its effects on cellular processes in cancer cells and the resulting phenotypical changes depending on lactate utilization, its blockade by MCT1 inhibitors such as AZD3965 is currently in clinical testing [51]. This evidence concerns the gene SLC16A1 and cancer.